Somatic SNCA Copy Number Variants in Multiple System Atrophy Are Related to Pathology and Inclusions

Monica Emili Garcia-Segura,1 Diego Perez-Rodriguez, PhD,1 Darren Chambers,2 Zane Jaunmuktane,1,3,4 and Christos Proukakis, PhD, FRCP1,4,5

1 Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK; 2 The Dubowitz Neuromuscular Centre, Division of Neuropathology, UCL Queen Square Institute of Neurology, University College London, London, UK; 3 Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, University College London, London, UK; 4 Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust, London, UK

ABSTRACT: Background: Somatic α-synuclein (SNCA) copy number variants (CNVs, specifically gains) occur in multiple system atrophy (MSA) and Parkinson’s disease brains. Objective: The aim was to compare somatic SNCA CNVs in MSA subtypes (striatonigral degeneration [SND] and olivopontocerebellar atrophy [OPCA]) and correlate with inclusions. Methods: We combined fluorescent in situ hybridization with immunofluorescence for α-synuclein and in some cases oligodendrocyte marker tubulin polymerization promoting protein (TPPP). Results: We analyzed one to three brain regions from 24 MSA cases (13 SND, 11 OPCA). In a region preferentially affected in one subtype (putamen in SND, cerebellum in OPCA), mosaicism was higher in that subtype, and cells with CNVs were 4.2 times more likely to have inclusions. In the substantia nigra, non-pigmented cells with CNVs and TPPP were about six times more likely to have inclusions.

Conclusions: The correlation between SNCA CNVs and pathology (at a regional level) and inclusions (at a single-cell level) suggests a role for somatic SNCA CNVs in MSA pathogenesis. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Key Words: snca; alpha-synuclein; mosaicism; multiple system atrophy; somatic mutation

Background

Multiple system atrophy (MSA) can be classified pathologically into striatonigral degeneration (SND), olivoponto-cerebellar atrophy (OPCA), and mixed.1 α-Synuclein, encoded by SNCA, forms aggregates, and glial cytoplasmic inclusions (GCIs) in oligodendrocytes are likely central to pathogenesis.2 Rare inherited SNCA mutations lead to synucleinopathies, generally classified as Parkinson’s disease (PD), often with dementia. These are most often copy number variants (CNVs), specifically gains, which increase mRNA,3 and disease severity depends on gene dosage.4 Patients with SNCA mutations frequently also have MSA features with GCIs,5-8 suggesting that SNCA mutations can also affect oligodendrocytes. As MSA is a sporadic disorder, with heritability less than 7%,9 a major role of mutations may appear unlikely. Mutations can, however, also be acquired post-zygotically. These are termed “somatic” and lead to mosaicism, the presence of cells with genetic differences in an organism. Somatic mutations, including CNVs, occur in brain,10 have a role in several neuropsychiatric and neurodevelopmental conditions,11 and may also have a role in neurodegeneration,12 and the asymmetry is often observed.13 Somatic SNCA mutations could contribute directly to the etiopathogenesis of sporadic synucleinopathies.14

We previously reported that somatic SNCA CNVs (gains) in the substantia nigra (SN) and cingulate cortex...
are more frequent in MSA and PD patients than in controls using fluorescent in situ hybridization (FISH).\textsuperscript{15,16} We also used single-cell whole genome amplification and low coverage sequencing to demonstrate somatic CNVs in about 30% of brain cells from two MSA cases, including a gain of SNCA.\textsuperscript{16} To further investigate the role of somatic SNCA CNVs in MSA, we have now compared their abundance (mosaicism level) in three different regions between SND and OPCA and correlated their presence with inclusions in the same cells.

**Methods**

Samples were provided by the UCL Queen Square Brain Bank for Neurological Disorders (Table S1) with informed consent for use of tissue in research and ethics approval by the UK National Research Ethics Service (07/MRE09/72). We analyzed 10-μm frozen sections from MSA patient brains from the SN at the level of the red nucleus or decussation of the superior cerebellar peduncle, putaminal striatopallidal fibers at the level of the anterior commissure (henceforth referred to as “putamen”), and cerebellar white matter. We performed FISH for SNCA copy numbers and a reference gene (unless otherwise stated) combined with immunofluorescence (IF) as described.\textsuperscript{17} For SNCA FISH, we used the same probe as before (Agilent SureFISH SNCA 4q.22.1, G110997R-8) and a chromosome 7 probe as reference (Agilent SureFISH G110902G-8) (Santa Clara, California, USA). IF staining for α-synuclein (mouse monoclonal 211, Santa Cruz, 1:200 dilution) (Dallas, Texas, USA) was performed in most experiments. In the SN, we divided cells based on neuromelanin (NM) presence into NM+ (dopaminergic neurons) and NM− (glia and other neurons). For oligodendrocyte detection, we used a rabbit monoclonal antibody to tubulin polymerization promoting protein (TPPP) (Abcam ab92305, 1:50 dilution) (Cambridge, UK), interpreting a nuclear signal as positive and omitting the reference FISH probe to simultaneously detect α-synuclein aggregates. Staining was visualized using Alexa 647 goat anti-mouse for α-synuclein and Alexa 488 goat anti-rabbit for TPPP (Life Technologies, 1:500 dilution) (Carlsbad, California, USA). All experiments were performed blinded to disease subtype. Images were obtained on a Leica epifluorescence microscope coupled to an ORCAII Digital CCD camera (Hamamatsu, Shizuoka, Japan) and controlled by Leica Application Suite X (Leica, Wetzlar, Germany) as z-Stacks of 16 images (separated by 0.5 μm) using appropriate fluorescence filters and brightfield in the SN for NM. Statistical analysis was performed using GraphPad Prism (v.9). Pairwise comparisons were performed using unpaired t test, two sided, as normal distribution was confirmed using the Kolmogorov–Smirnov test. 2 × 2 and 2 × 3 tables were analyzed using χ² test.

**Results**

We first investigated whether mosaicism level in a given region differs based on the involvement of the region in each MSA subtype by studying putamen, mostly affected in SND; cerebellum, mostly affected in OPCA; and SN, equally affected in both. We analyzed 5967 cells, derived from at least one brain region from 24 MSA cases (13 SND, 11 OPCA), including all three from 14 (Tables S1 and S2). We calculated percentage SNCA mosaicism as the percentage of cells containing unique gains of SNCA (more than two SNCA copies, two copies of reference) divided by the total number of cells with no other detectable genomic aberration, that is, two copies of reference and more than two copies of SNCA, as before (Fig. 1A; all individual results are presented in detail in Table S3). In the cerebellum, mosaicism was significantly higher in OPCA (11.1% vs. 8.6%), whereas in the putamen, it was significantly higher in SND (9.9% vs. 8.5%). Furthermore, comparing these figures within each subtype revealed that mosaicism in SND was significantly higher in putamen than cerebellum (P = 0.006) and that mosaicism in OPCA was significantly higher in cerebellum than putamen (P = 0.003). Therefore, in a region preferentially affected in one MSA subtype, mosaicism is higher in that subtype, and in a given subtype of MSA, mosaicism is higher in a preferentially affected rather than a relatively spared region. In the SN it was similar in both subtypes, and this was also true when divided into dopaminergic neurons (NM+) and other cells (NM−), which are mostly oligodendrocytes\textsuperscript{18} (Fig. S1).

To avoid possible sectioning artifacts, and for consistency with our previous work,\textsuperscript{15,16} we did not include cells with gains of both probes, or losses of either probe, in the main analysis. Gains of both probes could represent true gains of both SNCA and the reference. They could also, however, be artifacts if multiple complete or partial nuclei were counted together, despite the care taken to avoid this. We noted only 18 cells with gains of both probes (0.29%): 14 of which were in the SN (0.59%), 3 in the cerebellum (0.16%), and 1 in the putamen (0.05%) (P < 0.0001). Half of the SN cells with gains of both probes had more SNCA than reference copies, consistent with the excess SNCA signals observed overall (six 4 SNCA/3 reference, one 5 SNCA/3 reference). We also reviewed gains of the reference probe alone. As in previous work with other reference probes,\textsuperscript{15,16} these were extremely rare (18 cells, 0.29%). Of these, 15 were in the SN (0.63%), whereas there were only
2 in the cerebellum (0.1%) and 1 in the putamen (0.05%) (\(P < 0.0001\)).

We next performed further analysis of experiments where FISH had been combined with \(\alpha\)-synuclein IF to compare the proportion of inclusions in different regions and subtypes and determine whether \(\alpha\)-synuclein inclusions occur preferentially in cells with SNCA CNVs (Fig. 1B; 5007 cells). Inclusions were more frequent in the cerebellum and putamen in the subtype where each is preferentially affected (cerebellum: OPCA 14.3%, SND 6.9%, \(P < 0.0001\); putamen: SND 10.3%, OPCA 5.5%, \(P = 0.0002\)). In the SN, inclusion prevalence was similar (SND 7.7%, OPCA 7.4%). As previous data had suggested increased inclusions in the SN in cells with CNVs, in a specific pattern (NM+ cells in Lewy body disorders and NM− cells in MSA-SND),\textsuperscript{16} we determined whether CNV presence is associated with a higher risk of inclusion in the same cell in each region and subtype (Table 1). Cells with CNVs were 4.2 times more likely to have inclusions in the preferentially affected region in each subtype (cerebellum in OPCA, putamen in SND). In the relatively spared regions, a significant effect, but smaller (2.7 times), was observed only in SND. In the SN, NM− cells with CNVs were about six times more likely to have inclusions in both subtypes, but an association with inclusions in NM+ cells was observed only in OPCA. We conclude that CNVs are associated with inclusions in the same cells in affected regions.

As there is significant heterogeneity of oligodendrocytes,\textsuperscript{19} we hypothesized that the association of CNVs and inclusions may occur only in those with certain expression profiles. TPPP/P25α is an oligodendrocyte protein that contributes to \(\alpha\)-synuclein aggregation.\textsuperscript{20-23} We combined SNCA FISH with IF for TPPP and \(\alpha\)-synuclein in SN from four additional MSA cases (two SND, two OPCA; 473 cells, of which 382 NM−; Table S4). We found robust nuclear TPPP staining in 53.4% of NM− cells, within which inclusions were present more often in TPPP+ cells (11.8%,...
Validation will overall, 26 relative risk (RR) for presently be measured together with DNA FISH. However, demonstrated increased mRNA, which cannot thus determine pathology subtype. We have not, or more. The mosaicism level did not depend on TPPP than two. The mosaicism level did not depend on TPPP presence (+) or absence (−). Significant results are in bold font. Abbreviations: CNV, copy number variant; MSA, multiple system atrophy; NM, neuromelanin; OPCA, olivopontocerebellar atrophy; SN, substantia nigra; SND, striatonigral degeneration.

vs. 4.5% TPPP−, \( P = 0.015 \)). In these experiments, as no reference FISH probe was used, % SNCA mosaicism was calculated as the proportion of cells with more than two SNCA copies among all cells with two copies or more. The mosaicism level did not depend on TPPP presence, with CNVs in 10.1% of TPPP+ and 7.8% of TPPP− cells (\( P = 0.5 \)), but the association between CNVs and inclusions was observed only in TPPP+ cells. These were six times more likely to have an inclusion if they had a CNV in SN and 5.7 times in OPCA (\( P = 0.017 \) and 0.0009, respectively; Table S4). Among NM− cells in the SN, a cell with both a CNV and TPPP expression may therefore be most likely to develop inclusions.

**Conclusions**

We provide the first evidence in MSA, and to our knowledge in any neurodegenerative disorder, that the level of a potentially relevant somatic mutation in a brain region is higher in the disease subtype where this region is preferentially affected but similar in a region equally affected in both subtypes. The higher prevalence of cells with genomic instability beyond SNCA gains, that is, gains of the reference alone or of both probes, in the SN merits further investigation. We confirm a significant association between CNVs and inclusions in the same cells, in regions affected in each subtype, but reduced or absent in a region relatively spared. Presence of a CNV may lead to increased SNCA mRNA, which could be of particular importance in oligodendrocytes, where endogenous expression is low.\(^{22,24}\) This would lead to increased availability of α-synuclein to aggregate locally, and mosaicism levels in different regions could thus determine pathology subtype. We have not, however, demonstrated increased mRNA, which cannot presently be measured together with DNA FISH. Furthermore, we cannot exclude the possibility that α-synuclein aggregation causes DNA damage\(^{25}\) leading to somatic mutations such as SNCA CNVs, although even in this case a CNV may further potentiate aggregation.\(^{12}\) Inclusion development in an oligodendrocyte with a CNV may be facilitated by TPPP expression, which leads to the highly toxic MSA α-synuclein strain.\(^{23}\) Validation will require larger studies, including other regions, and detailed characterization of cells with CNVs to determine whether all (excluding dopaminergic neurons) are oligodendrocytes. It will also be crucial to determine the timing at which CNVs arise and whether enhancement of DNA repair is a valid target, for example, by augmenting nicotinamide adenine dinucleotide, as suggested in PD.\(^{26}\) Overall, our results suggest a direct role of somatic SNCA CNVs in MSA etiopathogenesis and determination of pathological subtype.

**Acknowledgments:** Brain tissue samples were provided by the UCL Queen Square Brain Bank for neurological disorders. We are grateful to the individuals who donated their brains.

**Data Availability Statement**

Brain samples used in this study, with corresponding results, can be made available by formal application directly to the Queen Square Brain Bank.

**References**


Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.
Author Roles


M.E.G.-S.: 1B, 1C, 3B
D.P.-R.: 1A, 1B, 1C, 2C, 3B
D.C.: 1B, 1C, 3B
Z.J.: 1A, 1B, 1C, 2C, 2B
C.P.: 1A, 1B, 1C, 2A, 2B, 2C, 3A

Full financial disclosures of all authors for the previous 12 months

ZJ: grant from Aligning Science Across Parkinson’s; editorial board member of Acta Neuropathologica. CP: grants from Aligning Science Across Parkinson’s and MSA Trust; editorial board member of Frontiers in Neurology (neurogenetics section).